About the Authors
- Robert S. Wallis
-
* E-mail: rswallis@gmail.com
Current address: Aurum Institute, Johannesburg, South Africa
Affiliation Formerly Pfizer Inc, Groton, Connecticut, United States of America
- Rodney Dawson
-
Affiliation University of Cape Town, Cape Town, South Africa
- Sven O. Friedrich
-
Affiliation Division of Medical Physiology, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
- Amour Venter
-
Affiliation Medical Research Council Centre for Molecular and Cellular Biology, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
- Darcy Paige
-
Affiliation Pfizer, Groton, Connecticut, United States of America
- Tong Zhu
-
Affiliation Pfizer, Groton, Connecticut, United States of America
- Annette Silvia
-
Affiliation Pfizer, Groton, Connecticut, United States of America
- Jason Gobey
-
Affiliation Pfizer, Groton, Connecticut, United States of America
- Craig Ellery
-
Affiliation Pfizer, Groton, Connecticut, United States of America
- Yao Zhang
-
Affiliation Pfizer, Groton, Connecticut, United States of America
- Kathleen Eisenach
-
Affiliation University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America
- Paul Miller
-
Current address: Infection Innovative Medicines Unit, AstraZeneca Pharmaceuticals, Waltham, Massachusetts, United States of America
Affiliation Formerly Pfizer Inc, Groton, Connecticut, United States of America
- Andreas H. Diacon
-
Affiliation Division of Medical Physiology, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
Competing Interests
The authors have read the journal's policy and have the following conflicts: RSW, DP, TZ, AS, JG, CE, YZ and PM are/were Pfizer employees, and/or shareholders at the time the study was conducted, whose company funded this study. KE of the University of Arkansas was a paid consultant to Pfizer Inc in regards to the study design. Rights to sutezolid were acquired by Sequella, Inc. in 2013. There are no further patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: RSW RD AV SF DP TZ AS JG CE YZ KE PM AHD. Performed the experiments: RD AV SF AHD. Analyzed the data: YZ TZ RSW. Contributed reagents/materials/analysis tools: RSW. Wrote the paper: RSW RD AV SF DP TZ AS JG CE YZ KE PM AHD.